Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC in locally advanced gastric cancer
NCT04595929Recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Feb 2020
- Primary completion
- Oct 2021
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of Cisplatin micelle injection (HA132) and pegylated liposomal doxorubicin in gastric cancer (GC), sponsored by First Saint Petersburg State Medical University. Started Feb 2020; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)pegylated liposomal doxorubicin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04595929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04595929.